Exportin 1 (XPO1), also known as chromosome maintenance 1 protein (CRM1), is the main transporter for hundreds of proteins like tumor suppressors, growth regulatory factors, oncoprotein mRNAs and others. Its upregulation leads to the inactivation of the tumor suppressor anti-neoplastic function in many cancers and logically is associated with poor prognosis. Selective inhibitors of nuclear export (SINE) are a new generation of XPO1 inhibitors that are being investigated as a promising targeted anti-cancer therapy. Selinexor is the first generation of SINE compounds that is being evaluated in many clinical trials involving solid tumors and hematological malignancies with its two approved indications for relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma. Here, we comprehensively review the current knowledge of selinexor and next generations of the SINE compounds in lymphoid and myeloid malignancies.

• Klíčová slova
• Exportin 1 protein, Leukemia, Lymphoma, Myeloma, Selective inhibitors of nuclear export, Selinexor,
• MeSH
• aktivní transport - buněčné jádro účinky léků   MeSH
• cílená molekulární terapie MeSH
• hematologické nádory diagnóza   farmakoterapie   etiologie   mortalita   MeSH
• hydraziny farmakologie   terapeutické užití   MeSH
• karyoferiny antagonisté a inhibitory   MeSH
• lidé MeSH
• management nemoci MeSH
• prognóza MeSH
• protein exportin 1 MeSH
• protinádorové látky farmakologie   terapeutické užití   MeSH
• receptory cytoplazmatické a nukleární antagonisté a inhibitory   MeSH
• triazoly farmakologie   terapeutické užití   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• hydraziny MeSH
• karyoferiny MeSH
• protinádorové látky MeSH
• receptory cytoplazmatické a nukleární MeSH
• selinexor MeSH Prohlížeč
• triazoly MeSH